Maternal inflammatory markers for chorioamnionitis in preterm prelabour rupture of membranes : a systematic review and meta-analysis of diagnostic test accuracy studies by Koech Etyang, Angela et al.
RESEARCH Open Access
Maternal inflammatory markers for
chorioamnionitis in preterm prelabour
rupture of membranes: a systematic review
and meta-analysis of diagnostic test
accuracy studies
Angela Koech Etyang1* , Geoffrey Omuse2, Abraham Mwaniki Mukaindo1 and Marleen Temmerman1
Abstract
Background: There is no consensus on the role of inflammatory markers in identifying chorioamnionitis in preterm
prelabour rupture of membranes (PPROM). We set out to evaluate the accuracy of maternal blood C-reactive
protein (CRP), procalcitonin and interleukin 6 (IL6) in diagnosis of histological chorioamnionitis and/or funisitis
(HCA/Funisitis) in PPROM.
Methods: We searched MEDLINE, EMBASE and The Cochrane Library from inception to January 2020 for studies where
maternal blood CRP, procalcitonin or IL6 was assessed against a reference standard of HCA/Funisitis in PPROM. The
Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2) tool was used to assess methodological quality.
Hierarchical summary receiver operating characteristic (SROC) models were used to construct summary curves.
Bivariate models were used to obtain summary estimates for studies with the same cut-off.
Results: We included 23 studies reporting HCA/Funisitis in 902 of 1717 women, median prevalence 50% (inter-quartile
range 38–57). Of these studies, 20 were prospective cohort design and 3 were retrospective cohort. Eleven studies
reported the index test against a reference standard of HCA and/or funisitis, 10 reported HCA alone and 2 reported
funisitis alone. Many studies had high risk of bias scores on the QUADAS-2 assessment but low concerns for
applicability. Sensitivity and specificity for CRP ≥ 20mg/L (5 studies, 252 participants) was 59% (95% CI 48–69) and 83%
(95% CI 74–89) respectively. SROC curves are provided for each index test. At selected specificity of 80%, the
sensitivities for CRP (all cut-offs, 17 studies, 1404 participants), PCT ( all cut-offs, 6 studies, 231 participants) and IL6 (all
cut-offs, 5 studies, 299 participants) were 59%(95% CI 52–68), 56%(95% CI 50–69) and 52% (95% CI 50–86) respectively.
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Conclusions: There is insufficient evidence to support use of CRP, procalcitonin or IL6 in maternal blood for diagnosis
of HCA/Funisitis in PPROM. This review followed recommended methodology and data analytic methods that made
the most of the data regardless of the different cut-offs used. However, the evidence is based on few studies with
generally small sample sizes, poor-quality scores and substantial heterogeneity. There is a need for good-quality
diagnostic accuracy studies to better assess the role of these biomarkers in PPROM.
Systematic review registration: PROSPERO registration number: CRD42015023899, registered on 8 October 2015.
Keywords: Inflammatory markers, Chorioamnionitis, C-reactive protein, Procalcitonin, Interleukin 6
Background
In preterm prelabour rupture of membranes (PPROM),
the decision for delivery is a delicate balance that con-
siders risks of preterm birth versus risks of infection from
continuing pregnancy [1, 2]. Typically, expectant manage-
ment is carried out until the patient develops clinical signs
suggestive of infection or until an appropriate gestation
for safe delivery is reached. If clinical features of infection
or inflammation are detected, then usually delivery is
initiated. These clinical features can be thought of as an
existing test. Inflammatory markers may form a suitable
replacement test in place of the clinical features as the
latter often become evident late or remain absent even in
the presence of chorioamnionitis [3]. If inflammatory
markers assayed in maternal blood are found to be suffi-
ciently accurate in the diagnosis of chorioamnionitis, they
can influence clinical decision-making and reduce reliance
on clinical features alone. Early diagnosis of infection can
advise therapeutic interventions such as delivery and anti-
biotic administration [4].
Maternal serum offers a readily accessible biological
sample for assay of inflammatory markers and is pre-
ferred over alternative samples such as amniotic fluid
which are harder to obtain [5] and not always available
in non-specialist centres. Cord blood is an alternative
sample, but its availability only after delivery precludes
its use in decision-making during pregnancy.
There is no consensus on a suitable reference standard
for diagnosis of chorioamnionitis [5–8]. We opted to use
histologic chorioamnionitis (HCA) and/or funisitis as
the reference standard for this review because standard
criteria for ascertainment have existed for many years
[9], its assessment is objective where these criteria are
applied and there is good correlation with neonatal out-
comes [10].
Several studies have evaluated maternal inflammatory
markers for diagnosis of chorioamnionitis in PPROM
with varying results and recommendations. Current
guidelines [1, 4] do not recommend use of these markers
alone for diagnosing infection in PPROM, but despite
this, many clinicians continue to use these tests in
PPROM with the results potentially influencing clinical
decision-making [11]. Older reviews suggested CRP is
useful in diagnosis of chorioamnionitis [12], but more
recent systematic reviews [6–8] give no clear evidence
for this recommendation. Prior systematic reviews have
evaluated the role of C-reactive protein (CRP) in
PPROM [6, 7] and do not recommend its use for pre-
dicting chorioamnionitis. However, these reviews were
based on few studies [6–8], demonstrated marked
heterogeneity [6, 7] and used data analysis methods that
are not recommended [6, 8]. Several studies assessing
CRP and other inflammatory markers have since been
published.
The objective of this review was to evaluate the accur-
acy of maternal blood inflammatory markers: C-reactive
protein (CRP), procalcitonin (PCT) and interleukin 6
(IL6) in the diagnosis of histologic chorioamnionitis
and/or funisitis in PPROM and to assess the sources of
heterogeneity in estimates of diagnostic accuracy.
Methods
This systematic review of diagnostic accuracy employed
methodological approaches recommended in the
Cochrane Handbook for Systematic Reviews of Diagnos-
tic Test Accuracy [13] and followed a prospectively
prepared protocol [14] registered with PROSPERO
CRD42015023899. This report complies with the Pre-
ferred Reporting Items for Systematic Reviews and
Meta-analyses of Diagnostic Test Accuracy Studies, the
PRISMA-DTA statement [15], and PRISMA-DTA
checklists are provided as Additional file 1.
The inclusion criteria were studies of pregnant women
with PPROM before 37 completed weeks of gestation.
The tests of interest were CRP, PCT and IL6 performed
on a maternal blood sample obtained prior to delivery,
with any cut-off and any method of assay. The reference
standard for chorioamnionitis was histologic chorioam-
nionitis and/or funisitis (HCA/Funisitis)—where a
definition or diagnostic criteria was provided or a speci-
fication of histologic or microscopic assessment of the
placenta was indicated or where the placenta was
assessed by a pathologist. Any study design where the
results of the index test were compared with the refer-
ence standard and reported data allowed extraction of 2
× 2 data was eligible.
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We aimed to identify relevant studies published in
peer-reviewed journals. We searched MEDLINE,
EMBASE and The Cochrane Library from inception to 5
Jan 2020 and performed manual searches on reference
lists of included articles and previous related reviews.
The search strategy included a combination of subject
headings and free-text terms related to the index test
and target population only. We did not use any filters or
search terms for the study design [16, 17] nor did we
include the term ‘diagnostic study’. There were no re-
strictions for language, publication dates or geographical
setting in the electronic search. Where the database
allowed, the limit for ‘Humans’ was applied. The search
strategy is provided in Additional file 2.
Initial screening of titles and/or abstracts and subse-
quent in-depth review of full texts were done independ-
ently by 2 reviewers each (AKE, GO and AMM).
Disagreements were resolved by consensus that included
a third reviewer (AMM). Despite no restrictions for
language in the electronic search and abstract screening,
studies with non-English/non-French full texts were
excluded due to anticipated difficulties in obtaining
translations. Data extraction was done independently by
2 reviewers (AKE and GO) using a custom data extrac-
tion form that was piloted on 3 randomly selected
eligible studies. Extracted fields included study charac-
teristics (study design, setting, year of study, inclusion
criteria, gestational age range), characteristics of the
index tests (index test, method of assay, cut-off(s), tim-
ing of index test relative to delivery), clinical manage-
ment of participants (antibiotic use, steroids, tocolysis)
and indices of diagnostic accuracy. True positive, true
negative, false positive and false negative values (2 × 2
data) for each test in each study and for each cut-off re-
ported were extracted or calculated from indices of diag-
nostic accuracy provided. In studies with a wide range of
clinical diagnoses (e.g. including preterm labour with
intact membranes) or wide gestational age range (e.g.
including term PROM), 2 × 2 data was extracted for the
PPROM subgroup where this was reported separately.
Authors of otherwise eligible studies but with missing,
unclear or conflicting 2 × 2 data were contacted by
email.
A review-specific checklist derived from the Quality
Assessment of Diagnostic Accuracy Studies 2 (QUA-
DAS-2) [18] tool was used to assess the methodological
quality of included studies. Assessments were done by 2
reviewers (GO and AKE) independently with disagree-
ments resolved by consensus. Studies with a low risk of
bias in patient selection were those that employed con-
secutive or random sampling and excluded women with
clinical features of chorioamnionitis and/or preterm
labour at the time of presentation with PPROM. Patient
selection criteria that were potential sources of bias
included selecting patients based on availability of other
tests or completeness of records, restricting patients to a
particular duration of PPROM and excluding women
with common pregnancy-related or medical conditions.
For the reference standard, objective and blinded assess-
ment of the placenta was considered to have low risk of
bias. The study flow and timing was considered to be of
low risk of bias if the interval between blood sampling
and delivery (proxy for placental assessment) was ≤ 72 h
and if data were analysed and reported for ≥ 90% of
included participants.
We obtained study estimates of sensitivity, specificity
and corresponding 95% confidence intervals (CI) and
displayed these on coupled forest plots. Meta-analysis
was carried out if the number of studies in each index
test category was ≥ 3. All reference standards were
considered together as one. Summary receiver operator
characteristic (SROC) curves were constructed for each
test regardless of cut-off using the Rutter and Gatsonis’
Hierarchical SROC (HSROC) model [19]. HSROC
analysis was conducted using the NLMIXED procedure
in SAS® (University Edition 2016, Cary, NC), and the
parameter estimates obtained were then inputted into
Cochrane Review Manager (RevMan, version 5.3,
Copenhagen) for construction of the curves [20]. The
HSROC analysis is a random effects model, and it
accounts for the correlation between sensitivity and spe-
cificity across the studies with changes in threshold [19,
20]. It makes the most use of the data as studies are
pooled regardless of differences in cut-offs [20]. For
studies using the same cut-off, we used bivariate analysis
to obtain summary sensitivity and specificity and corre-
sponding 95% CIs. To aid understanding of the findings,
we derived normalised frequencies assuming a patient
population of 100 women and a prevalence obtained
from the median prevalence of the included studies [21].
For SROC curves, we chose a false positive rate and de-
rived corresponding sensitivity and confidence intervals
from the model [21].
Heterogeneity assessment for studies using the same
cut-off was carried out by visually inspecting the 95%
prediction regions on SROC curves [20]. For the other
studies, further exploration for causes of heterogeneity
was carried out where the number of studies exceeded 5
and each subgroup had at least 2 studies. We aimed to
evaluate the following as possible sources: assay type,
pre-specified cut-off, interval between sampling and de-
livery and the risk of bias score in the patient selection
domain of the QUADAS-2. These characteristics were
added as binary covariates to the HSROC models in
SAS® (University Edition 2016, Cary, NC). Pairs of SROC
curves were constructed by inputting the parameters
into Cochrane Review Manager (RevMan, version 5.3,
Copenhagen). For simplicity, the shape parameter was
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assumed to be the same in the 2 subgroups. Chi-squared
test was used to compare the 2-Log likelihoods to test
for differences in SROC curves between subgroups.
Covariates were applied to the model one at time and
curves compared for each characteristic in turn. We did
not construct models with more than one covariate due
to limited power in the setting of few studies [20, 22].
We performed sensitivity analysis to investigate the
possible influence of including studies with a narrower
gestational age range (limiting the review to studies with
gestational age above 24 weeks), year of publication
(limiting the review to studies published after year 2000)
and limiting the review to studies with low concerns for
applicability on the patient selection domain of the
QUADAS-2 assessment. Pairs of SROC plots were
constructed and comparison done visually [20]. No as-
sessment of publication bias was performed as included
studies were few or too heterogeneous [23, 24].
Results
Results of the search
The search yielded 3020 unique records of which 25 (25
publications, 23 unique studies) were included (Fig. 1).
Twenty-one of the 46 potentially eligible studies were
excluded due to missing or unclear 2 × 2 data. More in-
formation on these studies is provided in Additional file
3. No additional data was obtained from contacted
authors.
Characteristics of included studies
The studies were published between 1983 and 2019 and
conducted in 13 countries. Twenty studies were pro-
spective cohort design and 3 studies retrospective cohort
design. All were conducted in hospital inpatient settings
with majority at teaching/university hospitals. In total,
there were 1717 participants, 902 of whom had HCA/
funisitis; median prevalence 50%; and inter-quartile
range 38% to 57%. Characteristics of included studies
are summarised in Table 1.
All studies reported data for preterm gestation (< 37
weeks) at the time of prelabour rupture of membranes
(PROM), but the specific gestational age range for eligi-
bility varied greatly among the included studies.
Methods used to establish gestational age were unre-
ported in most studies [26, 28–31, 34–36, 39, 41, 43, 45]
except for 5 [27, 32, 40, 44, 49] which used a combin-
ation of last menstrual period and ultrasound. Where re-
ported, diagnosis of PROM was made by clinical
assessment (speculum examination) with some studies
[27, 28, 31, 33, 35, 38, 40, 43–45, 49] conducting further
confirmatory testing on all or some of the patients.
Management of PPROM was largely expectant with
monitoring of fetal well-being, surveillance for clinical
features of chorioamnionitis and monitoring for signs of
labour. Use of antibiotics, steroids and/or tocolytics
where reported was universal or selective—dependent
on gestational age or clinical features. Reasons for deliv-
ery included gestational age greater than 34 weeks [36,
40, 45], failed tocolysis or refractory labour [26–28, 35],
completion of steroids or confirmed pulmonary maturity
[26, 27, 44], foetal distress/abnormal cardiotocogram
[26, 27, 35, 36, 44], suspected abruption [35] and/or
other obstetric complications [36, 40, 44]. Six studies
specified that clinical features of chorioamnionitis were
an indication for delivery [26, 28, 29, 36, 44, 49].
According to the definitions of reference standard pro-
vided, 11 studies [26, 28, 31, 35, 36, 40–44, 50] reported
the index test against a reference standard of HCA and/
or funisitis, 10 [27, 29, 30, 32, 34, 39, 45, 46, 48, 49]
reported HCA alone and 2 studies [33, 38] reported
funisitis alone. Characteristics of included studies are
outlined in Table 1. Studies evaluated the index tests
over a wide range of cut-offs. More characteristics of
index tests are provided in Additional file 4.
Methodological quality of included studies
Many studies were poorly reported, and 22 out of 23
were found to be at high risk of bias in at least 1 of the
4 domains of the QUADAS-2 (QUADAS-2 whiting) tool
(Fig. 2, Additional file 5). In the ‘Patient selection’ do-
main, we judged 14 of the 23 studies to be at high risk
of bias largely due to inappropriate exclusions such as
excluding women based on duration after PPROM [35,
38], not explicitly excluding women with clinical features
of chorioamnionitis at the time of PPROM or at the
time of admission [26, 27, 31, 34, 38, 40], basing exclu-
sions on availability or ability to perform other tests [31,
40, 45], excluding women due to missing data [34, 35,
50] and excluding women with common conditions and
complications of pregnancy that often coexist with
PPROM [32, 36, 39, 40]. In the ‘Index test’ domain, all
tests were considered to be ‘blinded’ because maternal
blood was collected before delivery and assessed on
automated assays. Studies where the cut-offs used were
not pre-specified [29, 31, 32, 35, 39, 43, 45, 49] but de-
termined from the study data were also deemed to be at
high risk of bias. Only 6 studies [27, 29, 33, 38, 40, 46]
explicitly reported blinding in placental assessment.
There were marked differences in the timing of collec-
tion of maternal blood, and many studies failed to report
this clearly [26, 34, 36, 40]. We assumed a ≤ 72-h inter-
val between maternal blood sampling and delivery to be
appropriate as we felt the relationship between the index
test and the outcome at placental assessment would be
preserved. Only 11 studies [28–31, 33, 35, 36, 38, 41, 42,
49] had samples drawn within this interval. Studies that
used samples obtained close to the time of admission or
the time of PPROM would be at higher risk of bias due
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to variable lengths of latency after PPROM. All included
studies had low concerns for applicability with regard to
the index test and reference standard. In the ‘Patient se-
lection’ domain, 5 studies [26, 27, 31, 35, 38] were
judged to have high concerns for applicability as they
did not explicitly report exclusion of contractions or ad-
vanced cervical dilatation (preterm labour).
Findings
Seventeen studies evaluated CRP as the index test, 6
evaluated the role of PCT and 5 evaluated IL6. Sensitiv-
ity and specificity pairs and their confidence intervals
are demonstrated in Fig. 3. The forest plot shows wide
variability in the sensitivity and specificity for each
index test group. Studies reported data against a wide
range of index test cut-offs (Fig. 3). Figures 4 and 5
show the various studies each plotted in ROC space as
a single sensitivity-specificity point. The sizes of the in-
dividual points reflect the study sample size, and the
scatter gives an impression of the heterogeneity in the
findings. For CRP, 5 studies reported findings at a cut-
off of 20 mg/L. A summary point of sensitivity and
specificity is provided for this test group, and the large
95% prediction region reflects substantial heterogeneity.
For the other test groups, a SROC curve is plotted for
the range of sensitivity and specificity from the
included studies. The closer the curve to the top left
corner, the better the overall accuracy. The wide scatter
of the study points in these plots suggests substantial
heterogeneity.
Fig. 1 Study flow diagram. PPROM, preterm prelabour rupture of membranes. HCA, histologic chorioamnionitis. Figure modified from the PRISMA
statement [25]
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Findings of heterogeneity assessments
There was some heterogeneity as demonstrated by the
95% prediction region on the SROC (Fig. 4) for the
studies reporting CRP at 20 mg/L. Further heterogeneity
assessments revealed likely sources as interval between
maternal blood sampling and delivery, nature of index
test cut-off (predetermined or not), risk of bias score in
the patient selection domain and assay type (Table 2,
Additional file 6).
Findings of sensitivity analysis
Sensitivity analysis for CRP were performed to assess the
influence of including studies based on gestational age
range, applicability concerns in the patient selection do-
main and year of publication. Year of publication was
not assessed for PCT and IL6 as all studies were
published after the year 2000. All IL6 studies had low
applicability concerns in the patient selection domain, so
this was not assessed. Results of the sensitivity analysis
are given in Table 2 and Additional file 7.
Findings of this diagnostic review are summarised in
the summary of findings table, Table 3.
Discussion
Main findings
The results of this review show the 3 tests have high
false positive rates (low specificity) and high false
negative rates (low sensitivity) in the diagnosis of
histologic chorioamnionitis and/or funisitis (see Sum-
mary of findings table—interpretation). These findings
Fig. 2 Risk of bias and applicability concerns graph [18] for included studies. CRP, C-reactive protein; PCT, procalcitonin; IL6, interleukin 6
Fig. 3 Forest plot showing sensitivity and specificity for included studies. TP—true positive, FP—false positive, FN—false negative, TN—true
negative, CI—confidence interval, CRP—C-reactive protein, PCT—procalcitonin, IL6—interleukin 6. Studies are ordered by specificity in
descending order for each index test group
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Fig. 4 Summary ROC curve: C-reactive protein for histologic chorioamnionitis and/or funisitis; Curve 1 - C-reactive protein all studies. Curve 2 - C-
reactive protein at 20 mg/L cutoff
Fig. 5 Summary ROC curves: interleukin 6 and procalcitonin for histologic chorioamnionitis and/or funisitis
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are obtained in the background of few included studies
with generally small sample sizes, poor quality assess-
ments and substantial heterogeneity.
Strengths and limitations
The findings of this review need to be evaluated with the
knowledge of various strengths and weaknesses both of
the included studies and those of the review methods.
Included studies were few in number and generally had
small sample sizes. This affects the precision and applic-
ability of the findings, especially in the face of substantial
heterogeneity. Studies were of poor quality with a high
risk of bias in 1 or more domains. Poor reporting limited
the assessment of methodological quality and applicabil-
ity of many of the included studies. Findings of these
studies are likely to be affected by various biases due to
poor study design.
We have conducted this review following recommen-
dations of the Cochrane group of diagnostic reviews [20]
and following a prospectively registered protocol [14].
We employed a broad search strategy with search terms
that did not include the reference standard and did not
use a filter for ‘diagnostic studies’ [51]. However, a large
proportion of potentially eligible studies were excluded
due to inability to extract 2 × 2 data. Despite contacting
authors of these studies, no additional data were ob-
tained. We only included studies published in English
and French and failed to obtain full texts of 6 articles.
Our review was also limited to published studies only,
limiting its representativeness.
Our review question limited the studies to those ad-
dressing a specific clinical condition in pregnancy,
PPROM. This reduced chances of pooling together
test accuracy indices that are different due to differ-
ences in patient characteristics and probability of dis-
ease [52]. All included studies had low concerns for
applicability in the index test and reference standard
domains. High applicability concerns arose in the pa-
tient selection domain particularly due to failure to
explicitly exclude patients with preterm labour and
perhaps due to poor reporting of inclusion criteria in
some studies. We explored potential sources of het-
erogeneity where possible, but some subgroup analysis
could not be carried out due to the few studies. We
assumed the same shape (parallel curves) in compar-
ing SROCs of subgroups due to the small number of
Table 2 Heterogeneity assessments and sensitivity analysis
Heterogeneity assessments Sensitivity analysis
Characteristic
assessed
Findings p valueƚ Characteristic assessed Findings
CRP (all
cut-offs)
Predetermined
cut-off
Studies using a predetermined
cut-off had slightly lower accuracy
0.003 Gestational age range Excluding studies that included GA < 24
weeks resulted in a slightly lower accuracy
Interval between
sampling and
delivery
Studies > 72 h had lower accuracy < 0.001 Applicability concerns in
patient selection domain
Excluding studies with high concerns did
not change the SROC curve
Risk of bias in
patient selection
domain
Studies with low risk score had
lower accuracy
< 0.001 Publication year
after 2000
Excluding studies published before year
2000 yielded a slightly lower accuracy
Assay type Studies with CRP assays after
standardisation (year 1993) had
lower accuracy
< 0.001
PCT Predetermined
cut-off
Studies using a predetermined
cut-off had slightly lower accuracy
0.026 Gestational age range Excluding studies that included GA < 24
had no effect
Interval between
sampling and
delivery
No difference 0.178 Applicability concerns in
patient selection domain
Excluding studies with high concerns resulted
in a much lower accuracy and a change in
shape of the curve
Risk of bias in
patient selection
Studies with low risk score had
lower accuracy
< 0.001 Publication year
after 2000
Not assessed as all studies were published
after year 2000
IL6 Predetermined
cut-off
Not assessed as 1 subgroup had
< 2 studies
Gestational age range Excluding studies that included GA < 24
weeks resulted in a slightly higher accuracy
and change in shape of SROC curve
Interval between
sampling and
delivery
Studies ≤ 72 h had lower accuracy < 0.001 Applicability concerns in
patient selection domain
Not assessed as all studies had low
applicability concerns
Risk of bias in
patient selection
Not assessed as 1 subgroup had
< 2 studies
Publication year
after 2000
Not assessed as all studies were published
after year 2000
More information is provided in Additional files 6 and 7
ƚLikelihood ratio test
CRP C-Reactive Protein, PCT Procalcitonin, SROC Summary Receiver Operating Characteristic, IL6 Interleukin 6
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studies—this would miss situations where the accur-
acy of the test varied with threshold in a different
manner in the 2 subgroups compared.
Previous reviews [6, 7] examining the role of inflam-
matory markers in diagnosis of chorioamnionitis in
PPROM had few studies, high between-study heterogen-
eity and differences in cut-offs that prevented pooled
analysis. We identified more studies through our
broader search criteria. These reviews [6, 7] also used
methods of analysis that are no longer recommended.
We used HSROC analysis [19, 20], a method that
allowed pooling of studies with different cut-offs hence
making efficient use of the data and maximising power
[20]. We also assessed heterogeneity and identified likely
sources. Despite these differences, our findings are in
agreement with previous reviews that there is no
evidence to support use of CRP, PCT or IL6 in the
diagnosis of chorioamnionitis.
Conclusions
Implications for clinical practice
The proposed clinical role of the tests in PPROM is
to guide interventions such as delivery or expectant
management by appropriately identifying which preg-
nancies have chorioamnionitis. We have found insuffi-
cient evidence to recommend the use of either CRP,
PCT or IL6 in maternal blood as a solitary test for
the diagnosis of HCA/Funisitis in PPROM. Though it
is relatively easy to obtain maternal blood for labora-
tory evaluation of these markers, the high false
Table 3 Summary of findings table
Maternal inflammatory markers for chorioamnionitis in preterm prelabour rupture of membranes(PPROM): a systematic review and meta-analysis of
diagnostic test accuracy studies
Question In pregnant women with PPROM, can maternal serum inflammatory markers be used to diagnose chorioamnionitis?
Population Pregnant women with PPROM
Studies Any study design where the index test is compared against the reference standard
Index test C-reactive protein (CRP), procalcitonin (PCT) and interleukin 6 (IL6) assessed in maternal serum before delivery
Reference
standard
Histologic chorioamnionitis (HCA) and/ or funisitis
Prevalence
of disease
Median prevalence 50% (range 21–70%, IQR 38 to 57%)
23 studies with a total of 1717 pregnant women with PPROM, 902 of whom had HCA/funisitis
Quality Included studies were generally of poor quality with all studies at high risk of bias in at least one domain (QUADAS-2). There were few
studies with high applicability concerns and only in the patient selection domain.
Index test Studies
(participants)
Sensitivity
(95% CI)
Specificity
(95% CI)
Heterogeneity Sensitivity
analysis
Interpretation: assuming a patient population of
100 pregnant women with PPROM and
prevalence of 50%*
Correctly
diagnosed
cases (TP)
Missed
cases
(FN)
Unnecessary
interventions
(FP)
True
reassurance
of no
disease (TN)
CRP at
20 mg/L†
5 (252) 59%
(47.7–69.0)
83%
(74.0–89.2)
High heterogeneity
despite common cut-off
30 21 9 42
CRP at all
cut-offs‡
17 (1404) 59%
(52.0–67.6)
80% Partially explained by
nature of cut-off used,
sampling interval, risk of
bias in the patient selec-
tion domain and type of
CRP assay
Sensitive to
gestational age
range for study
inclusion and
year of
publication
30 20 10 40
PCT at all
cut-offs‡
6(231) 56%
(49.9–68.9)
80% Partially explained by
nature of cut-off used
and risk of bias in the pa-
tient selection domain of
QUADAS-2
Sensitive to
applicability
concerns score
in the patient
selection domain
of QUADAS-2
28 22 10 40
IL6 at all‡
cut-offs
5 (299) 52%
(50.0–85.8)
80% Partially explained by
sampling interval
Sensitive to
gestational age
range for study
26 24 10 40
The results on this table should not be interpreted in isolation from the results in the main body of the text of the review
*Median prevalence from included studies
†Estimate from the summary point from bivariate analysis
‡Sensitivity derived from HSROC analysis assuming a specificity of 80% (false positive rate of 20%)
CRP C-Reactive Protein, PCT Procalcitonin, IL6 Interleukin 6
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positive rates mean the tests should not be relied
upon for important clinical decisions such as delivery.
False positive results would have greater negative im-
plications as they would result in iatrogenic preterm
delivery with no indication. False positives at earlier
gestations greatly could significantly impact neonatal
outcome and survival.
Whether use of these tests should be recommended
also depends on existence of and diagnostic performance
of alternative tests in similar roles. Inflammatory
markers in amniotic fluid may have better diagnostic
performance than tests in maternal blood [53] but are
limited by the complexity of amniotic fluid collection,
increased costs and lower acceptability to women. Alter-
native approaches may be to combine these tests with
other laboratory and clinical markers or to conduct
serial tests [4]. This review did not examine these alter-
native tests and approaches.
Implications for research
This review has demonstrated several weaknesses in the
included studies and significant heterogeneity in findings
that limit our ability to make reliable conclusions. There
is need for better designed diagnostic accuracy studies
where an effort is placed to reduce the various sources
of bias as outlined in our quality assessments. In
addition to assessing the role of the inflammatory
marker, the contribution of other clinical and laboratory
factors could be assessed jointly by regression modelling.
Several studies included in this report were poorly re-
ported. Use of the standards for Reporting of Diagnostic
Accuracy—STARD [54]—could reduce this and enable
reviewers to correctly assess quality of studies and make
more data available for review and meta-analysis.
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